News Image

Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.

By Mill Chart

Last update: Dec 19, 2023

Exploring Growth Potential: HALOZYME THERAPEUTICS INC (NASDAQ:HALO) and Its Base Formation. Growth investors seek promising revenue and EPS growth, and HALOZYME THERAPEUTICS INC has come under our scrutiny for potential growth investing. While it's crucial to do your own research, we've detected HALOZYME THERAPEUTICS INC on our screen for growth with base formation, suggesting it merits a closer look.

A Closer Look at Growth for NASDAQ:HALO

ChartMill assigns a proprietary Growth Rating to each stock. The score is computed by evaluating various growth aspects, like EPS and revenue growth. We take into account the history as well as the estimated future numbers. NASDAQ:HALO was assigned a score of 8 for growth:

  • HALO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.96%, which is quite good.
  • HALO shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 42.34% yearly.
  • HALO shows a strong growth in Revenue. In the last year, the Revenue has grown by 34.42%.
  • Measured over the past years, HALO shows a quite strong growth in Revenue. The Revenue has been growing by 15.83% on average per year.
  • Based on estimates for the next years, HALO will show a very strong growth in Earnings Per Share. The EPS will grow by 25.42% on average per year.
  • HALO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.85% yearly.

Health Assessment of NASDAQ:HALO

ChartMill assigns a proprietary Health Rating to each stock. The score is computed by evaluating various liquidity and solvency ratios and ranges from 0 to 10. NASDAQ:HALO was assigned a score of 7 for health:

  • HALO has an Altman-Z score of 3.48. This indicates that HALO is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of HALO (3.48) is better than 74.75% of its industry peers.
  • HALO has a better Debt to FCF ratio (4.24) than 94.85% of its industry peers.
  • A Current Ratio of 7.63 indicates that HALO has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 7.63, HALO is doing good in the industry, outperforming 68.27% of the companies in the same industry.
  • HALO has a Quick Ratio of 6.51. This indicates that HALO is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 6.51, HALO is in the better half of the industry, outperforming 62.62% of the companies in the same industry.

Evaluating Profitability: NASDAQ:HALO

ChartMill utilizes a Profitability Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of profitability ratios and margins, both in absolute terms and in comparison to industry peers. NASDAQ:HALO has earned a 8 out of 10:

  • HALO has a Return On Assets of 13.41%. This is amongst the best in the industry. HALO outperforms 98.50% of its industry peers.
  • Looking at the Return On Equity, with a value of 101.89%, HALO belongs to the top of the industry, outperforming 99.83% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 14.39%, HALO belongs to the top of the industry, outperforming 97.67% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for HALO is significantly above the industry average of 13.03%.
  • The 3 year average ROIC (36.78%) for HALO is well above the current ROIC(14.39%). The reason for the recent decline needs to be investigated.
  • HALO has a better Profit Margin (32.53%) than 98.50% of its industry peers.
  • In the last couple of years the Profit Margin of HALO has grown nicely.
  • The Operating Margin of HALO (40.35%) is better than 98.84% of its industry peers.
  • HALO's Operating Margin has improved in the last couple of years.
  • HALO has a better Gross Margin (76.68%) than 85.55% of its industry peers.

How do we evaluate the setup for NASDAQ:HALO?

ChartMill takes into account not only the Technical Rating but also assigns a Setup Rating to each stock. This rating, on a scale of 0 to 10, reflects the degree of consolidation observed based on short-term technical indicators. Currently, NASDAQ:HALO exhibits a 8 setup rating, indicating its consolidation status in recent days and weeks.

Although the technical rating is bad, HALO does present a nice setup opportunity. Prices have been consolidating lately and the volatility has been reduced. A pullback is taking place, which may present a nice opportunity for an entry. There is very little resistance above the current price. Very recently a Pocket Pivot signal was observed. This is another positive sign.

Our Strong Growth screener lists more Strong Growth stocks and is updated daily.

For an up to date full fundamental analysis you can check the fundamental report of HALO

Check the latest full technical report of HALO for a complete technical analysis.

Disclaimer

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

HALOZYME THERAPEUTICS INC

NASDAQ:HALO (4/26/2024, 7:00:02 PM)

After market: 38.88 +0.31 (+0.8%)

38.57

+0.11 (+0.29%)

HALO News

News Imagea day ago - Halozyme Therapeutics, Inc.Mahesh Krishnan Elected to Halozyme's Board of Directors

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr....

News Image2 days ago - InvestorPlace3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition

Many fortunes have been made with a fortuitous investment in a biotech stock at the right time. That time might be now.

News Image4 days ago - Halozyme Therapeutics, Inc.Halozyme to Report First Quarter 2024 Financial and Operating Results

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2024 financial and operating results...

News Image4 days ago - ChartmillNASDAQ:HALO is not too expensive for the growth it is showing.

NASDAQ:HALO stands out as a growth opportunity that won't break the bank.

News Image11 days ago - ChartmillInvestors should take notice of NASDAQ:HALO—it offers a great deal for the fundamentals it presents.

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is an undervalued gem with solid fundamentals.

News Image14 days ago - Market News VideoNotable Two Hundred Day Moving Average Cross - HALO
News Imagea month ago - BusinessInsiderThe 3 Best Biotech Stocks to Buy in Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech is an industry full of opportunity. It’s also known as one of the...

News Imagea month ago - InvestorPlaceThe 3 Best Biotech Stocks to Buy in Q2 2024

Biotech can be a risky industry for investors, but we've done the legwork for you with these three biotech stocks for Q2.

News Imagea month ago - Market News VideoFirst Week of May 17th Options Trading For Halozyme Therapeutics (HALO)
News Imagea month ago - Investor's Business DailyMadrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark

On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago.

News Imagea month ago - InvestorPlace7 Biotech Stocks to Buy as Sector Rotation Ramps Up

With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation.

News Image2 months ago - Halozyme Therapeutics, Inc.Halozyme to Participate in Upcoming Investor Conferences

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is...

HALO Links
Follow us for more